Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial  Dr Ken M Kunisaki, MD, Prof Dennis E Niewoehner, MD, Gary Collins, MS, Bitten Aagaard, RN, Nafisah B Atako, MSc, Elzbieta Bakowska, MD, Amanda Clarke, BM, Giulio Maria Corbelli, MS, Ernest Ekong, MD, Prof Sean Emery, PhD, Elizabeth B Finley, ANP, Eric Florence, MD, Rosa M Infante, MD, Cissy M Kityo, MD, Juan Sierra Madero, MD, Daniel E Nixon, DO, Prof Ellen Tedaldi, MD, Prof Jørgen Vestbo, DMSc, Prof Robin Wood, DSc [Med], Prof John E Connett, PhD  The Lancet Respiratory Medicine  Volume 4, Issue 12, Pages 980-989 (December 2016) DOI: 10.1016/S2213-2600(16)30319-8 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Respiratory Medicine 2016 4, 980-989DOI: (10.1016/S2213-2600(16)30319-8) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 ART use, HIV RNA, and CD4 T-cell counts Differences between randomised treatment arms in frequency of antiretroviral therapy (ART) use (A, blue circles and green triangles), HIV RNA of 200 copies per mL or less (A, red circles and blue triangles), and mean CD4 T-cell counts (B), as a function of follow-up time in study. The Lancet Respiratory Medicine 2016 4, 980-989DOI: (10.1016/S2213-2600(16)30319-8) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Distribution of number of follow-up spirometry tests collected The Lancet Respiratory Medicine 2016 4, 980-989DOI: (10.1016/S2213-2600(16)30319-8) Copyright © 2016 Elsevier Ltd Terms and Conditions